Skip to main content
ALIVUS LIFE SCIENCES LIMITED logo

ALIVUS LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · ALIVUS ISIN · INE03Q201024 LEI · 335800RYVA1DKP696G32 BSE.NS Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2022-02-14 Regulatory Filings
Country IN India
Listing BSE.NS ALIVUS

About ALIVUS LIFE SCIENCES LIMITED

https://www.alivus.com

Alivus Life Sciences Limited is a pharmaceutical organization dedicated to the formulation, production, and commercialization of a broad spectrum of healthcare solutions. The company operates across multiple therapeutic categories, including gastroenterology, anti-infectives, pain management, and nutritional supplements. Its product range includes diverse delivery formats such as tablets, capsules, syrups, and injectable medications. Alivus Life Sciences focuses on maintaining rigorous quality control protocols and manufacturing excellence to deliver reliable therapeutic outcomes. The company utilizes a robust distribution infrastructure to supply its pharmaceutical products to healthcare providers and patients, prioritizing the accessibility of essential medicines and the continuous expansion of its therapeutic portfolio.

Recent filings

Filing Released Lang Actions
Monitoring Agency Report
Regulatory Filings Classification · 95% confidence The document is titled 'Monitoring Agency Report for the Quarter ended 31st December, 2021' and is issued pursuant to SEBI regulations related to the utilization of IPO proceeds. It contains detailed financial data on the use of funds raised through an equity share issue, including cost of objects, progress, and deployment of unutilized proceeds. The document is a comprehensive report on the monitoring of issue proceeds, not a brief announcement or certification. It is not an annual or interim financial report, nor a management discussion or earnings release. The content aligns with a regulatory requirement to monitor and report on IPO proceeds utilization, which is a specific type of regulatory compliance report. Given the detailed financial and compliance nature, and the absence of other specific filing types matching this description, the best fit is Regulatory Filings (RNS), as it is a regulatory compliance report that does not fit other categories like Annual Report or Capital/Financing Update directly.
2022-02-14 English
Investor Presentation
Regulatory Filings
2022-02-08 English
Financial Result Updates
Regulatory Filings
2022-02-08 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is an invitation letter for an earnings call scheduled on February 9, 2022, for Glenmark Life Sciences Ltd. It provides dial-in numbers, registration details, and contact information. There is no financial data or results disclosed in this document; it is purely an announcement of the upcoming earnings call event. According to the classification rules, such documents are classified as Call Transcript (CT) only if they contain the full transcript of the call. Since this is only an invitation and announcement, it fits best under the Call Transcript (CT) category as it relates directly to the earnings call event, but since it is not a transcript, the best fit is the announcement of the earnings call, which is typically classified as Call Transcript (CT) in this context. Confidence is high due to clear identification of the document purpose.
2022-02-01 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice (2251 characters) addressed to stock exchanges regarding a scheduled Board Meeting to consider and approve unaudited financial results for the third quarter and nine months ended December 31, 2021. It references compliance with SEBI regulations and insider trading code but does not contain any financial data or the results themselves. The document is an announcement of an upcoming event (Board Meeting) and not the actual financial report or results. According to the 'Menu vs Meal' rule, such short notices announcing meetings or report approvals are classified as Regulatory Filings (RNS) rather than Interim Reports (IR) or Earnings Releases (ER).
2022-01-31 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a letter dated January 31, 2022, addressed to stock exchanges regarding a scheduled Board Meeting on February 8, 2022. The purpose of the meeting is to consider and approve the unaudited financial results for the third quarter and nine months ended December 31, 2021. The letter also mentions the closure of the trading window for insiders in compliance with insider trading regulations. The document does not contain any financial data or results itself but is an announcement about the upcoming board meeting and financial results approval. The document length is 2251 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a board meeting and financial results approval, not the financial report itself or a detailed management discussion.
2022-01-31 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.